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either edge of the Gemin 6/7 dimer to form an open ring edly provide some answers and more crucial insight
into the biogenesis of ribonucleoprotein particles.or a closed heptameric ring similar to the core domain
(Kambach et al., 1999) (Figure 1).
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LOX-1 Unlocked
The solution of the crystal structure of LOX-1, origi-
nally identified as the endothelial receptor for oxi-
edized LDL (Sawamura et al., 1997), has been reported
oby the Tate (Ohki et al., 2005) and Boyington groups
h(Park et al., 2005).
p
hOxidized low-density lipoprotein (OxLDL) is implicated
bin the pathogenesis of atherosclerosis, including both
athe formation of foam cells and the induction of endo-
athelial dysfunction (Ross, 1993). Several kinds of recep-
ators that are able to mediate the action of oxLDL in
Sthe vascular wall have collectively come to be termed
m“scavenger receptors,” although no conserved se-
lquences are present in the primary structures of the
sdifferent receptor classes. Among these receptors,
aLOX-1 is unique for its C-type lectin-like ligand binding
idomain and structurally belongs to the natural killer
(NK) cell receptor family (Chen et al., 2002). The human
LOX-1 gene is located within the NK cell receptor geneomplex on chromosome 12p12-p13 between AICL
nd CD94/NKG2.
The expression of LOX-1 is increased in hyperten-
ion, diabetes, and hyperlipidemia, and high expres-
ion of LOX-1 is found in atherosclerotic lesions. Inter-
stingly, enhanced expression of LOX-1 has also been
bserved in the endothelium of the prelesion areas of
yperlipidemic rabbits, suggesting that this expression
recedes the changes in vascular function induced by
yperlipidemia. In endothelial cells, activation of LOX-1
y OxLDL induces the upregulation of MCP-1, ICAM-1,
nd VCAM-1 expression, the release of the superoxide
nion, and a reduction in the release of NO, all of which
re known characteristics of “endothelial dysfunction.”
ince endothelial dysfunction enhances the recruit-
ent of leukocytes into the subendothelial space and
eads to inflammation, oxidative stress, and vasocon-
trictive changes, this pathological step is recognized
s the potential basis of the vascular diseases, includ-
ng atherosclerosis.
Besides OxLDL, LOX-1 also binds other ligands, in-cluding poly(I), acidic phospholipids, apoptotic cells,
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835platelets, leukocytes, and bacteria. (Honjo et al., 2003;
Kakutani et al., 2000; Oka et al., 1998). This suggests a
versatility of functions for LOX-1 in both pathological
and physiological conditions in vivo. In some animal
models of inflammation, LOX-1 promotes leukocyte in-
filtration as a cell-adhesion molecule and enhances in-
flammation. The broad range of ligand specificity in
part overlaps with other scavenger receptors and Toll-
like receptors (TLRs). In this sense, LOX-1 might be
involved in innate immunity. In point of fact, LOX-1 is
expressed in dendritic cells and is involved in antigen
presentation (Delneste et al., 2002), although its precise
roles in this immunological context have yet to be de-
termined.
On the other hand, LOX-1 has an interesting ligand
specificity. LOX-1 binds OxLDL and acetylated LDL, but
not native LDL. During oxidation, various changes oc-
cur to LDL, i.e., degenerative fragmentation of apolipo-
protein and its covalent modification by lipids. There-
fore, OxLDL may have several structural features
distinct from native LDL. Acetylated LDL is generated
by acetylation of the epsilon-amino group of apolipo-
protein in LDL. The major consequence is increased
negative charge, which also occurs with OxLDL. Simi-
larly, negatively charged phospholipids such as phos-
phatidylserine are recognized by LOX-1, but neutral
phospholipids such as phosphatidylcholine are not.
These findings suggest that the negative charge on li-
gands is of crucial importance for ligand recognition by
LOX-1. In fact, substitution of basic with neutral amino
acids greatly decreases the ligand binding capacity of
LOX-1. It is not clear whether there are additional com-
mon structural features among modified LDL, acidic
phospholipids, and poly(I).
From the crystal structures of LOX-1 reported by two
groups, we now have some clues toward understand-
ing the ligand-receptor interaction of LOX-1 (Ohki et al.,
2005; Park et al., 2005). In the structural models, the
ligand binding interface is hydrophobic except for the
basic spine, which is composed of arginine residues.
Ohki et al. (2005) pointed out that this is a structure
unique to LOX-1 compared with the related C-type lec-
tin-like molecules NKG2D and Ly49A. Furthermore,
they performed expression experiments of mutated
LOX-1 and observed that substitution of a single amino
acid in the basic spine, R208N, resulted in the greatest
loss of binding affinity for acetylated LDL, although
other arginine residues in the basic spine also contri-
buted to the binding of acetylated LDL (Ohki et al.,
2005). Together with the hydrophobic surface, the posi-
tive charge of the basic spine seems to provide the li-
gand specificity of LOX-1 for anionic lipids/lipoproteins.
The crystal structure of human LOX-1’s ligand bind-
ing domain has been successfully solved as a homodi-
meric structure with an intermolecular disulfide bond
(Ohki et al., 2005). Interestingly, a single amino acid
change, W150A, located in the homodimer interface re-
sulted in the loss of binding affinity for acetylated LDL
in their expression study. This suggests that an appro-
priate form of dimerization is needed for ligand recogni-
tion. It was also shown that the dimeric structurechanges depending on pH. As an endocytotic receptor,
decreasing pH in the endosome may change the di-
meric structure of LOX-1 and thus lead to the dissoci-
ation of ligands and a recycling of the receptor to the
cell surface.
The structure solved in the reported study (Ohki et
al., 2005) is not the ligand-receptor complex but the
receptor alone. Therefore, it has yet to be determined
how the structure of LOX-1 changes upon interaction
with ligands. However, a characteristic “empty cavity”
formed between the two LOX-1 molecules in a dimer
might be the key to understanding why a particular vari-
ety of molecule is recognized by LOX-1.
Among the scavenger receptors, LOX-1 is the first
molecule examined crystallographically. It has been a
mystery how these different classes of receptors recog-
nize the same molecules, including OxLDL, despite the
absence of a common sequence in primary structure.
The solution of the structure of LOX-1 may help unravel
of how the scavenger receptors/pattern recognition
molecules are able to bind a broad range of molecules,
and may also help in designing receptor antagonists
which might be useful in diseases related to endothelial
dysfunction, such as inflammation and atherosclerosis.
Additionally, genome analysis revealed a cluster of
C-type lectin-like molecules on the short arm of chro-
mosome 12, increasing the number of distinct mem-
bers of this interesting protein family. These proteins
may offer a good model for understanding molecular
evolution from both genomic and structural perspec-
tives.
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